Overview

All Sanguine study protocols and their resulting samples, which include all Sanguine at-home and apheresis collection programs, are conducted under an Institutional Review Board (IRB). Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant.

Sanguine’s human plasma is isolated and cryopreserved within one day to ensure optimal quality and integrity for research and therapeutic applications. Our rigorous processing methods preserve essential biomarkers, making our plasma an ideal choice for scientists and healthcare professionals seeking reliable, high-quality biospecimens. Plasma include verified diagnosis for disease state, and donor-reported allergies and infectious disease history.

Well-characterized plasma for Parkinson’s disease research supports studies on neurodegeneration, dopaminergic dysfunction, and therapeutic development for symptom management and disease modification.